Premier Biomedical (BIEI) 0.0127 $BIEI
Premier Biomedical and Advanced Technologies Solutions Agree to Forming Joint Venture in Pain Management, Treating Neuropathic and Localized Pain
Marketwire Canada - Mon Aug 01, 7:00AM CDT
EL PASO, TX--(Marketwired - Aug 1, 2016) - Premier Biomedical, Inc. (OTCQB: BIEI), a biotech research public company, and Advanced Technologies Solutions (ATS), a leader in natural ingredient pain relief compounds and delivery technologies, announced the signing of a Letter of Intent (LOI) to form a Joint Venture (JV) to manufacture and distribute products to treat neuropathic and other localized pain. The formation of this joint venture is expected to expedite the development of a series of topical and oral opioid-free pain treatments to compete in the $40 billion pain management segment of the U.S. healthcare market.
Premier Biomedical Confirms Consolidation of Debt
Marketwire Canada - Tue May 31, 11:00AM CDT
EL PASO, TX--(Marketwired - May 31, 2016) - Premier Biomedical, Inc. (OTCQB: BIEI) reported today that it has consolidated its debt to one lender, a move that the company believes will minimize the toxic impact that having multiple lenders had on the market for its stock.
Premier Biomedical Announces the Appointment of Dr. James Frincke to Chief Technical Officer Position
Marketwired - Tue May 24, 1:20PM CDT
EL PASO, TX--(Marketwired - May 24, 2016) - Premier Biomedical, Inc. (OTCQB: BIEI) announced the appointment of Dr. James Frincke to the position of Chief Technical Officer effective immediately. In this role, Dr. Frincke will report to the President and CEO of Premier, William A. Hartman. Dr. Frincke will retain his current position as a member of the company's Scientific Advisory board, which reports to Premier's co-founder and Chairman of the Scientific Advisory Board, Dr. Mitchell S. Felder, MD.
Traumatic Brain Injury Pipeline Market 2016 Covering 37 Key Players
PR Newswire - Fri Apr 08, 5:00AM CDT
This 2016 report provides an overview of the Traumatic Brain Injury therapeutic pipeline and helps enhance decision making capabilities to create effective counter strategies & gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
LPTN: 3.18 (-0.07), OMER: 11.22 (-0.12), ATHX: 2.01 (unch), KPTI: 7.76 (-0.32), CUR: 0.27 (unch)
Premier Biomedical, Inc. Engages Agent to Identify Suitable Joint Venture Partners in China and Europe
BusinessWire - Wed Mar 16, 9:00AM CDT
Premier Biomedical, Inc. (OTCQB: BIEI) announced that they have engaged the services of an agent affiliated with the Chinese pharmaceutical industry to seek out suitable joint venture partners in China and Europe. The agent will act in Premier's interests in locating and securing financing and suitable joint venture partners in China and Europe for the purposes of testing, registering and marketing medications and devices being developed by Premier for the treatment of various diseases, such as fibromyalgia, MS, and cancer.
Premier Biomedical Announces Intended $6 Million Investment by Brazilian Joint Venture Partner, Auramedi, to Manufacture, Market and Distribute Premier's New Technology Products
BusinessWire - Mon Feb 01, 8:30AM CST
Premier Biomedical, Inc.(OTCQB:"BIEI"
a biotech research company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer, as well as for fibromyalgia, neuropathy, atherosclerosis and muscular dystrophy confirmed today that its planned Brazilian joint venture partner, Auramedi Farmaceutica, Ltd., has announced its intention to invest up to BRL$25 Million (USD$ 6 Million) to establish facilities for the manufacture, distribution and sale of Premier Biomedical drugs and other treatments in Brazil and South America.
Premier Biomedical Files Provisional Patent Application on Second Drug to Treat Fibromyalgia, Neuropathic Pain, MS Symptoms, and Alcohol and Chemical Addiction
BusinessWire - Tue Jan 26, 8:30AM CST
Premier Biomedical, Inc.(OTCQB:"BIEI" a biotech research company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer, as well as for neurofibromatosis, atherosclerosis and muscular dystrophy, announced the filing of a provisional patent on a second drug to treat fibromyalgia, neuropathic pain, MS symptoms, and alcohol and chemical addiction. This new drug is in addition to Premier's existing Feldetrex(R) drug, to compete in this segment of the health care market representing an opportunity of $16B annually.
Premier Biomedical CEO in Radio Interview Discusses Core Technology, Immunotherapy, Neuropathy Medication and Planned Series of Joint Ventures in Brazil, Asia and Europe for 2016
BusinessWire - Tue Jan 19, 8:30AM CST
Premier Biomedical, Inc. (OTCQB:BIEI) a biotech research public company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer as well as potential novel therapies for neurofibromatosis, atherosclerosis and muscular dystrophy, announced that their President and CEO, William A. Hartman, was interviewed by Uptick Newswire's Everett Jolly, on his radio segment, "Stock Day," which focuses on OTC and small cap stock companies.
Premier Biomedical Announces $1.6mil Financing - Consolidates Funding Needs Through 2016
BusinessWire - Tue Jan 05, 11:00AM CST
Premier Biomedical, Inc. (OTCQB: "BIEI" a biotech research company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer, announced today that they have consolidated and secured financing via a convertible note with restricted shares per tranche to fund their aggressive development plans through 2016, when revenues from world-wide joint ventures are anticipated to meet their ongoing financial needs. The financing arrangement allows Premier to remove old debt from its books and consolidate financing with a single funding source, while meeting its medium-term cash needs.
Premier Biomedical Recognized for Huge Growth Potential
BusinessWire - Tue Dec 15, 11:00AM CST
Premier Biomedical, Inc.(OTCQB: "BIEI" a biotech research company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer, announced today that Seraphim Strategies, LLC has named Premier Biomedical, Inc. as one of five small cap stocks that they believed could experience huge growth potential.
Five Small Cap Stocks Experiencing Huge Growth Potential
ACCESSWIRE - Fri Dec 11, 7:18AM CST
DELRAY BEACH, FL / ACCESSWIRE / December 11, 2015 / In today's quickly evolving market, small cap stocks increasingly profile as a viable investment for those with a higher risk tolerance. While the global market stirs, newer, smaller companies continue to claim larger portions of industry shares, and surprising names begin to surface as possible leaders in their respective fields.
Scientist Working With Premier Biomedical Invited To Present Possible Breakthrough Findings on Chemotherapy Treatment at San Antonio Breast Cancer Symposium Educational Session
BusinessWire - Tue Dec 08, 11:00AM CST
Premier Biomedical, Inc. (OTCQB:BIEI) a biotech research company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer, announced today that one of the lead outside scientists working on their sponsored research has been invited to present his findings on the treatment of breast cancer, at an evening educational session sponsored by prIME Oncology, at the San Antonio Breast Cancer Symposium December 9, 2015.
Penny Stocks Alerts for Dominovas Energy, Agrieuro, Magnum Hunter Resources, Bioelectronics, EKSO BIONICS, and Premier Biomedical
PR Newswire - Wed Nov 18, 8:00AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Dominovas Energy (OTCMKTS: DNRG), Agrieuro (OTCBB: EURI), Magnum Hunter Resources (OTCMKTS: MHRC), Bioelectronics (OTCMKTS: BIEL), EKSO BIONICS (OTCBB: EKSO), and Premier Biomedical (OTCMKTS: BIEI).
MHR: 0.15 (-0.11), EKSO: 4.04 (-0.01)
Due Diligence Report: Premier Biomedical - Cancer Research From the Comfort of Your Home
ACCESSWIRE - Wed Nov 18, 7:47AM CST
NEW YORK, NY / ACCESSWIRE / November 18, 2015 / Premier Biomedical Inc. (OTCMKTS: BIEI) a biotech research public company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer as well as potential novel therapies for neurofibromatosis, atherosclerosis and muscular dystrophy, announced today they have obtained exclusive rights to the recently allowed U.S. patent application, "Sequential Extracorporeal Treatment of Bodily Fluids", covering the basic technology underpinning Premier's on-going research into new, innovative treatments for many of today's most debilitating diseases.
Premier Biomedical Receives Notice of Allowance on Broad Base Patent Involving Innovative Extracorporeal Treatment Therapy - Premier Believes This May Lead To Cancer Cure
BusinessWire - Mon Nov 16, 11:00AM CST
Premier Biomedical, Inc. (OTCQB: BIEI) a biotech research public company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer as well as potential novel therapies for neurofibromatosis, atherosclerosis and muscular dystrophy, announced today they have obtained exclusive rights to the recently allowed U.S. patent application, "Sequential Extracorporeal Treatment of Bodily Fluids", covering the basic technology underpinning Premier's on-going research into new, innovative treatments for many of today's most debilitating diseases.
Premier Biomedical and Auramedi Farmaceutica Agree to Explore Forming Joint Venture in Brazil
BusinessWire - Thu Oct 15, 9:00AM CDT
Premier Biomedical, Inc. (OTCQB:BIEI), a biotech research public company, and Auramedi Farmaceutica Ltda (a Brazilian pharmaceutical company) announced the signing of a non-binding Letter of Intent (LOI) to enter into discussions to explore forming a possible Joint Venture (JV) in Brazil to develop Premier's various treatment technologies, and oversee the manufacture and distribution of the drugs and devices in the South American market initially. The formation of this joint venture is expected to expedite the approval, manufacture, sales and distribution of Premier's proprietary treatments. A third party has projected annual sales, in South America, for Premier's treatments at $400M by the year 2020.
Premier Biomedical, Inc. Accomplishments and Recent News
BusinessWire - Tue Sep 29, 7:00AM CDT
Premier Biomedical, Inc. (PBI) is a publicly traded (OTCQB:BIEI) research-based company that intends to discover and develop medical treatments targeting the treatment of heretofore incurable and/or hard-to-cure diseases.
Premier Biomedical and Advanced Technologies Solutions Agree to Forming Joint Venture in Pain Management, Treating Neuropathic and Localized Pain
Marketwire Canada - Mon Aug 01, 7:00AM CDT
EL PASO, TX--(Marketwired - Aug 1, 2016) - Premier Biomedical, Inc. (OTCQB: BIEI), a biotech research public company, and Advanced Technologies Solutions (ATS), a leader in natural ingredient pain relief compounds and delivery technologies, announced the signing of a Letter of Intent (LOI) to form a Joint Venture (JV) to manufacture and distribute products to treat neuropathic and other localized pain. The formation of this joint venture is expected to expedite the development of a series of topical and oral opioid-free pain treatments to compete in the $40 billion pain management segment of the U.S. healthcare market.
Premier Biomedical Confirms Consolidation of Debt
Marketwire Canada - Tue May 31, 11:00AM CDT
EL PASO, TX--(Marketwired - May 31, 2016) - Premier Biomedical, Inc. (OTCQB: BIEI) reported today that it has consolidated its debt to one lender, a move that the company believes will minimize the toxic impact that having multiple lenders had on the market for its stock.
Premier Biomedical Announces the Appointment of Dr. James Frincke to Chief Technical Officer Position
Marketwired - Tue May 24, 1:20PM CDT
EL PASO, TX--(Marketwired - May 24, 2016) - Premier Biomedical, Inc. (OTCQB: BIEI) announced the appointment of Dr. James Frincke to the position of Chief Technical Officer effective immediately. In this role, Dr. Frincke will report to the President and CEO of Premier, William A. Hartman. Dr. Frincke will retain his current position as a member of the company's Scientific Advisory board, which reports to Premier's co-founder and Chairman of the Scientific Advisory Board, Dr. Mitchell S. Felder, MD.
Traumatic Brain Injury Pipeline Market 2016 Covering 37 Key Players
PR Newswire - Fri Apr 08, 5:00AM CDT
This 2016 report provides an overview of the Traumatic Brain Injury therapeutic pipeline and helps enhance decision making capabilities to create effective counter strategies & gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
LPTN: 3.18 (-0.07), OMER: 11.22 (-0.12), ATHX: 2.01 (unch), KPTI: 7.76 (-0.32), CUR: 0.27 (unch)
Premier Biomedical, Inc. Engages Agent to Identify Suitable Joint Venture Partners in China and Europe
BusinessWire - Wed Mar 16, 9:00AM CDT
Premier Biomedical, Inc. (OTCQB: BIEI) announced that they have engaged the services of an agent affiliated with the Chinese pharmaceutical industry to seek out suitable joint venture partners in China and Europe. The agent will act in Premier's interests in locating and securing financing and suitable joint venture partners in China and Europe for the purposes of testing, registering and marketing medications and devices being developed by Premier for the treatment of various diseases, such as fibromyalgia, MS, and cancer.
Premier Biomedical Announces Intended $6 Million Investment by Brazilian Joint Venture Partner, Auramedi, to Manufacture, Market and Distribute Premier's New Technology Products
BusinessWire - Mon Feb 01, 8:30AM CST
Premier Biomedical, Inc.(OTCQB:"BIEI"
a biotech research company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer, as well as for fibromyalgia, neuropathy, atherosclerosis and muscular dystrophy confirmed today that its planned Brazilian joint venture partner, Auramedi Farmaceutica, Ltd., has announced its intention to invest up to BRL$25 Million (USD$ 6 Million) to establish facilities for the manufacture, distribution and sale of Premier Biomedical drugs and other treatments in Brazil and South America. Premier Biomedical Files Provisional Patent Application on Second Drug to Treat Fibromyalgia, Neuropathic Pain, MS Symptoms, and Alcohol and Chemical Addiction
BusinessWire - Tue Jan 26, 8:30AM CST
Premier Biomedical, Inc.(OTCQB:"BIEI"
a biotech research company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer, as well as for neurofibromatosis, atherosclerosis and muscular dystrophy, announced the filing of a provisional patent on a second drug to treat fibromyalgia, neuropathic pain, MS symptoms, and alcohol and chemical addiction. This new drug is in addition to Premier's existing Feldetrex(R) drug, to compete in this segment of the health care market representing an opportunity of $16B annually. Premier Biomedical CEO in Radio Interview Discusses Core Technology, Immunotherapy, Neuropathy Medication and Planned Series of Joint Ventures in Brazil, Asia and Europe for 2016
BusinessWire - Tue Jan 19, 8:30AM CST
Premier Biomedical, Inc. (OTCQB:BIEI) a biotech research public company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer as well as potential novel therapies for neurofibromatosis, atherosclerosis and muscular dystrophy, announced that their President and CEO, William A. Hartman, was interviewed by Uptick Newswire's Everett Jolly, on his radio segment, "Stock Day," which focuses on OTC and small cap stock companies.
Premier Biomedical Announces $1.6mil Financing - Consolidates Funding Needs Through 2016
BusinessWire - Tue Jan 05, 11:00AM CST
Premier Biomedical, Inc. (OTCQB: "BIEI"
a biotech research company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer, announced today that they have consolidated and secured financing via a convertible note with restricted shares per tranche to fund their aggressive development plans through 2016, when revenues from world-wide joint ventures are anticipated to meet their ongoing financial needs. The financing arrangement allows Premier to remove old debt from its books and consolidate financing with a single funding source, while meeting its medium-term cash needs. Premier Biomedical Recognized for Huge Growth Potential
BusinessWire - Tue Dec 15, 11:00AM CST
Premier Biomedical, Inc.(OTCQB: "BIEI"
a biotech research company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer, announced today that Seraphim Strategies, LLC has named Premier Biomedical, Inc. as one of five small cap stocks that they believed could experience huge growth potential. Five Small Cap Stocks Experiencing Huge Growth Potential
ACCESSWIRE - Fri Dec 11, 7:18AM CST
DELRAY BEACH, FL / ACCESSWIRE / December 11, 2015 / In today's quickly evolving market, small cap stocks increasingly profile as a viable investment for those with a higher risk tolerance. While the global market stirs, newer, smaller companies continue to claim larger portions of industry shares, and surprising names begin to surface as possible leaders in their respective fields.
Scientist Working With Premier Biomedical Invited To Present Possible Breakthrough Findings on Chemotherapy Treatment at San Antonio Breast Cancer Symposium Educational Session
BusinessWire - Tue Dec 08, 11:00AM CST
Premier Biomedical, Inc. (OTCQB:BIEI) a biotech research company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer, announced today that one of the lead outside scientists working on their sponsored research has been invited to present his findings on the treatment of breast cancer, at an evening educational session sponsored by prIME Oncology, at the San Antonio Breast Cancer Symposium December 9, 2015.
Penny Stocks Alerts for Dominovas Energy, Agrieuro, Magnum Hunter Resources, Bioelectronics, EKSO BIONICS, and Premier Biomedical
PR Newswire - Wed Nov 18, 8:00AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Dominovas Energy (OTCMKTS: DNRG), Agrieuro (OTCBB: EURI), Magnum Hunter Resources (OTCMKTS: MHRC), Bioelectronics (OTCMKTS: BIEL), EKSO BIONICS (OTCBB: EKSO), and Premier Biomedical (OTCMKTS: BIEI).
MHR: 0.15 (-0.11), EKSO: 4.04 (-0.01)
Due Diligence Report: Premier Biomedical - Cancer Research From the Comfort of Your Home
ACCESSWIRE - Wed Nov 18, 7:47AM CST
NEW YORK, NY / ACCESSWIRE / November 18, 2015 / Premier Biomedical Inc. (OTCMKTS: BIEI) a biotech research public company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer as well as potential novel therapies for neurofibromatosis, atherosclerosis and muscular dystrophy, announced today they have obtained exclusive rights to the recently allowed U.S. patent application, "Sequential Extracorporeal Treatment of Bodily Fluids", covering the basic technology underpinning Premier's on-going research into new, innovative treatments for many of today's most debilitating diseases.
Premier Biomedical Receives Notice of Allowance on Broad Base Patent Involving Innovative Extracorporeal Treatment Therapy - Premier Believes This May Lead To Cancer Cure
BusinessWire - Mon Nov 16, 11:00AM CST
Premier Biomedical, Inc. (OTCQB: BIEI) a biotech research public company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer as well as potential novel therapies for neurofibromatosis, atherosclerosis and muscular dystrophy, announced today they have obtained exclusive rights to the recently allowed U.S. patent application, "Sequential Extracorporeal Treatment of Bodily Fluids", covering the basic technology underpinning Premier's on-going research into new, innovative treatments for many of today's most debilitating diseases.
Premier Biomedical and Auramedi Farmaceutica Agree to Explore Forming Joint Venture in Brazil
BusinessWire - Thu Oct 15, 9:00AM CDT
Premier Biomedical, Inc. (OTCQB:BIEI), a biotech research public company, and Auramedi Farmaceutica Ltda (a Brazilian pharmaceutical company) announced the signing of a non-binding Letter of Intent (LOI) to enter into discussions to explore forming a possible Joint Venture (JV) in Brazil to develop Premier's various treatment technologies, and oversee the manufacture and distribution of the drugs and devices in the South American market initially. The formation of this joint venture is expected to expedite the approval, manufacture, sales and distribution of Premier's proprietary treatments. A third party has projected annual sales, in South America, for Premier's treatments at $400M by the year 2020.
Premier Biomedical, Inc. Accomplishments and Recent News
BusinessWire - Tue Sep 29, 7:00AM CDT
Premier Biomedical, Inc. (PBI) is a publicly traded (OTCQB:BIEI) research-based company that intends to discover and develop medical treatments targeting the treatment of heretofore incurable and/or hard-to-cure diseases.
